A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution
The resolution of the acute inflammatory response is governed by phagocytes actively clearing apoptotic cells and pathogens. Biosynthesis of the specialized pro-resolving mediators (SPMs) is pivotal in the resolution of inflammation their roles in innate immune cells. Resolvin E4 (RvE4: 5S,15S-dihyd...
Saved in:
Published in | Frontiers in immunology Vol. 11; p. 631319 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
10.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The resolution of the acute inflammatory response is governed by phagocytes actively clearing apoptotic cells and pathogens. Biosynthesis of the specialized pro-resolving mediators (SPMs) is pivotal in the resolution of inflammation
their roles in innate immune cells. Resolvin E4 (RvE4: 5S,15S-dihydroxy-eicosapentaenoic acid) is a newly uncovered member of the E-series resolvins biosynthesized from eicosapentaenoic acid (EPA) recently elucidated in physiologic hypoxia. This new resolvin was termed RvE4 given its ability to increase efferocytosis of apoptotic cells by macrophages. Herein, we report on the total organic synthesis of RvE4 confirming its unique structure, complete stereochemistry assignment and function. This synthetic RvE4 matched the physical properties of biogenic RvE4 material, i.e. ultra-violet (UV) absorbance, chromatographic behavior, and tandem mass spectrometry (MS
) fragmentation, as well as bioactivity. We confirmed RvE4 potent responses with human M2 macrophage efferocytosis of human apoptotic neutrophils and senescent red blood cells. Together, these results provide direct evidence for the assignment of the complete stereochemistry of RvE4 as 5
,15
-dihydroxy-6
,8
,11
,13E,17
-eicosapentaenoic acid and its bioactions in human phagocyte response. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Janos G. Filep, Université de Montréal, Canada Reviewed by: Gabrielle Fredman, Albany Medical College, United States; Joan Clària, Hospital, Clínic de Barcelona, Spain; Lucy V. Norling, Queen Mary University of London, United Kingdom This article was submitted to Inflammation, a section of the journal Frontiers in Immunology These authors share first authorship |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2020.631319 |